Exclusive Journals Coverage

Exclusive Journals Coverage articles provide quick insight and additional author perspectives on select studies recently published in Journal of Clinical Oncology and Journal of Oncology Practice.

Apr 28, 2014
The study—in which the CNS stimulant modafinil was given to patients with cancer-related fatigue (CRF)— showed the drug to have no benefit over placebo, although interestingly, both treatments brought about clinically significant changes in CRF. 
Apr 14, 2014
“The data suggests that in the post-dissemination era [i.e., contemporary patients], elderly patients over 65 undergoing robotic-assisted radical prostatectomy have the same risk of complications, readmissions, and additional cancer therapies as those who get open surgery" . . .
Mar 24, 2014
Jagsi and her colleagues focused on several specific measures of “financial decline,” including: patients’ perception of whether they were worse off financially since diagnosis and whether this was due to the breast cancer, total out-of-pocket expenses and how these were financed . . .
Mar 12, 2014
ASCO confers Special Awards to recognize researchers, physicians, patient advocates, and leaders of the global oncology community who, through their work in clinical oncology, cancer research, or public and government advocacy, have made significant contributions to the field of cancer care. Among this year's awardees are a researcher and Nobel...
Mar 11, 2014
 An Interview with ASCO Volunteer - Claude Denham, MD
Mar 11, 2014
   Navneet Singh, MD, DM,
: Postgraduate
Institute of Medical
Education and Research,
in Chandigarh, India
Member since: 2008
Specialties: Thoracic
Mar 11, 2014
Last February, ASCO launched ASCO International – a portfolio of international programs that improve cancer care, particularly in low- and middle-income countries – and a commitment to expand that portfolio over the next four years. This launch was made in concert with the broader recognition by the international community of the current and...
Mar 10, 2014
This current study comes on the heels of a previous 2010 mogamulizumab study from Japan, a country in which peripheral NK/T-cell neoplasms account for 25% of all non-Hodgkin lymphomas (NHLs); in Western countries, by comparison, peripheral NK/T-cell neoplasms account for 10% of all NHL’s.
Feb 24, 2014
Nearly a third of participants didn’t recall discussing fertility issues with their doctors before they started therapy,” said Dr. Ruddy, suggesting that doctors might be missing an important window of opportunity . . .
Feb 18, 2014
“In other words, if you achieve event-free survival [EFS] at 24 months, the overall likelihood of survival in the next five years is now essentially the same as it was prior to your diagnosis,” said Matthew Maurer, MS, first author of the study . . .